Software Engineer 1

Cepheid, a Danaher company, will unveil the third-generation GeneXpert system at the Association for Diagnostics & Laboratory Medicine Annual Scientific Meeting on 28 July. The new system maintains the simplicity and workflows of previous versions whilst introducing a touchscreen interface and redesigned software. At launch, the system will support Cepheid's existing menu of US FDA-cleared tests. Future capabilities are designed to include high-plex panel testing, faster results, and potential integration with next-generation sequencing workflows. The system preserves true random-access testing, allowing laboratories to process samples as they arrive rather than in batches. The compact four-module configuration will begin shipping to US customers in the coming months. Higher-capacity configurations are currently in development.

Merck cements Life Science leadership with $11.3B Bio-Techne acquisition. Friday, June 26, 2026 The life science tools market is heating up with Merck's blockbuster $11.3 billion acquisition of Bio-Techne. This strategic move is designed to cement the company's leadership in a rapidly growing sector and signals a major consolidation trend that is actively reshaping the industry for competitors and investors alike. Audio Brief (2:45 listen) The life science tools market, the critical "picks and shovels" infrastructure for the biopharmaceutical revolution, is witnessing a significant consolidation wave. In a landscape where scale and portfolio breadth are paramount, major players are aggressively pursuing M&A to secure long-term growth and competitive advantage. The latest blockbuster move comes from Merck, which has announced a definitive agreement to acquire Bio-Techne for an enterprise value of approximately $11.3 billion. This transaction is more than a simple expansion; it's a calculated maneuver to fortify Merck's leadership in high-growth areas like cell and gene therapy, proteomics, and diagnostics, signaling an intensified competitive environment for peers like Thermo Fisher Scientific and Danaher. A strategic bolt-on to cement leadership. Merck's acquisition of Bio-Techne is a clear reflection of its strategy to build an end-to-end offering for the biopharma industry through its Life Science business sector. While Merck already possesses a formidable portfolio, particularly in bioprocessing (the manufacturing of biologic drugs), the addition of Bio-Techne provides critical assets in the upstream research and discovery and quality control phases. * Strategic Rationale: The primary driver for this deal is the complementary nature of the two portfolios. Bio-Techne is a market leader in high-quality proteins, antibodies, and immunoassays - essential, high-margin consumables used extensively in academic research, drug discovery, and clinical diagnostics. These products fit seamlessly into Merck's existing research solutions business, creating significant cross-selling opportunities. By integrating Bio-Techne's reagent and small instrument capabilities, Merck can offer its customers a more comprehensive workflow solution, from initial discovery to final manufacturing. * Valuation Context: The US$73 per share cash offer, representing an $11.3 billion enterprise value, reflects the high strategic value placed on premium life science assets. Companies like Bio-Techne are highly attractive due to their strong brand recognition, intellectual property, and "razor-and-blade" business model, which generates predictable, recurring revenue from consumables. While the implied valuation multiple is substantial, it is in line with recent transactions in the sector, where acquirers are willing to pay a premium for assets that offer both market leadership and exposure to the fastest-growing segments of healthcare innovation. * Market Positioning: This deal significantly strengthens Merck's position as one of the top-tier suppliers to the global life science industry. It narrows the gap with larger, more diversified competitors and enhances Merck's "one-stop-shop" appeal. For large pharmaceutical and emerging biotech clients, the ability to source a wider range of critical reagents and instruments from a single, trusted partner simplifies procurement and can de-risk their supply chains - a crucial consideration in the post-pandemic era. Reshaping the competitive landscape. Merck's move is set to send ripples across the life science tools sector, forcing competitors to reassess their own strategic positions. The industry has long been characterized by a race for scale, and this acquisition raises the stakes considerably. For decades, the market has been dominated by a handful of large consolidators. This transaction reaffirms that aggressive M&A remains the primary tool for growth and market share capture. Competitors will now face a more formidable Merck, armed with a deeper portfolio in proteomics and diagnostics. This will likely spur further consolidation as other players look to fill gaps in their own offerings or acquire new technologies to stay competitive. The acquisition particularly amplifies Merck's capabilities in the burgeoning cell and gene therapy (CGT) space. Bio-Techne provides critical analytical and quality control tools used to characterize and release these complex therapies. By combining these with its own viral vector manufacturing solutions, Merck can offer a more integrated and compelling value proposition to CGT developers, a market segment poised for exponential growth. This strategic depth will be difficult for smaller, more specialized players to replicate. The path forward. The successful integration of Bio-Techne will be the immediate focus for Merck's leadership. Capturing the promised revenue and cost synergies will require a deft hand in merging distinct corporate cultures and aligning complex product roadmaps and sales channels. However, the strategic logic underpinning the deal appears sound and compelling. This acquisition is a bold statement of intent from Merck. It underscores a commitment to leading the life science tools market not just in established areas like bioprocessing but across the entire research and development continuum. For the industry at large, it signals that the era of transformative M&A is far from over. As the pace of biomedical innovation continues to accelerate, the race to supply the scientists and manufacturers on the front lines will only grow more intense. Analyze your own CIM. Upload a CIM and get financials, risks, and valuation in seconds.

Versant Diagnostics expands collaboration with Leica Biosystems as PRW Laboratories becomes first to deploy Aperio GT Elite solution. Milestone deployment reflects growing demand for high-throughput, AI-enabled digital pathology workflows Leica Biosystems Listen with Speechify Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Versant Diagnostics, an independent physician services company actively engaged in next-generation digital pathology, announce an expanded collaboration to advance digital pathology adoption. PRW Laboratories, in partnership with Versant Diagnostics and Versant DermPath, has become the world's first laboratory to deploy the recently launched Aperio GT Elite solution. Designed for high-throughput, time-critical digital pathology workflows, the Aperio GT Elite scanner helps accelerate slide processing and review with minimal manual intervention and rework. It can scan as fast as 22 seconds per slide and integrate LIS data to drive automated scanning protocols based on criteria such as tissue or stain type. "For digital pathology to truly advance, innovation must translate into faster, more confident decisions for laboratories and ultimately, the patients they serve," said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. "With the Aperio GT Elite, we are leveraging our deep pathology expertise to help customers move from slide to insight faster through a connected, high-throughput workflow that reduces manual steps and adapts to their real-world needs. This launch reflects our long-term commitment to delivering scalable, end-to-end solutions that enable labs to adopt digital pathology with confidence and accelerate the impact of every review." The deployment reflects growing adoption of high-throughput, AI-enabled digital pathology workflows and builds on a longstanding collaboration between Leica Biosystems and Versant Diagnostics. Before adding the Aperio GT Elite solution, Versant Diagnostics leveraged the Leica Biosystems Aperio GT 450 scanner to digitize whole-slide images, alongside Indica Labs' HALO AP(R) document as their image management solution. "When we started our digital journey, we weren't simply looking for an equipment vendor - we were looking for a true partner who shared our vision for the future of patient care," said Lola Leibensperger, Versant Diagnostics' Chief Operating Officer. "Becoming the first laboratory network in the world to implement Leica Biosystems' Aperio GT Elite scanners at Versant Diagnostics and PRW Laboratories is a testament to that shared commitment. This milestone isn't just about adopting cutting-edge technology; it's about pioneering digital innovation together to enhance accuracy, streamline laboratory workflows, and ultimately deliver faster, more precise diagnostics for the patients who depend on us." "As digital pathology hardware and software continue to evolve rapidly, selecting a vendor is about more than choosing the best solutions available today - it is also about partnering with an organization that can provide ongoing access to innovation and support," said Clay Hillyer, Senior National Sales Director at Leica Biosystems. "As a global leader in digital pathology, Leica Biosystems is committed to delivering both advanced products and a robust innovation pipeline that helps customers deploy and scale digital pathology to its fullest potential. We are proud to continue that commitment to Versant Diagnostics and PRW Laboratories through this deployment of the Aperio GT Elite solution." The Aperio GT Elite solution is one of the most recent innovations within Leica Biosystems' comprehensive digital and computational pathology ecosystem and expands the company's portfolio of end-to-end solutions-the only provider in the industry to span the full anatomic pathology workflow. Leica Biosystems is trusted by 100% of the Top 50 Hospitals for Cancer, as well as the National Cancer Institute-Designated Cancer Centers, and holds the largest digital pathology instrument install base worldwide. With planned expansion and broader availability of the Aperio GT Elite solution across additional global markets, Leica Biosystems continues to enable access to high-performance digital pathology solutions worldwide. Add The Scientist as a preferred Google source to see more of its trusted coverage.